Company news
Seres Therapeutics, Inc. news in 2022
Seres Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
Seres Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
November 1, 2022
Seres Therapeutics Announces FDA Acceptance of Biologics License Application for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection for Priority Review
October 25, 2022
Seres Therapeutics Announces Completion of Rolling BLA Submission to FDA for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection
September 6, 2022
Seres Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates
August 2, 2022
Seres Therapeutics Announces $100 Million Registered Direct Offering of Common Stock
June 29, 2022
Seres Therapeutics Announces Confirmatory Results from Investigational Microbiome Therapeutic SER-109 ECOSPOR IV Open-Label Study in Recurrent C. Difficile Infection
June 6, 2022
Seres Therapeutics Presents Phase Ill Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting
May 21, 2022
Seres Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
May 3, 2022
Seres Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates
February 28, 2022
Seres Therapeutics Appoints Paula Cloghessy as Executive Vice President, Chief People Officer
February 7, 2022
Calls in 2022
Decks in 2022
- Corporate Update (June 2022)
Corporate update · 21 slides · Jun 7, 2022
- Investor Presentation (April 2022)
Investor deck · 22 slides · Apr 6, 2022
- Chardan's Microbiome and Metagenomics Summit (March 2022)
Conference · 20 slides · March 2022
- Investor Day (January 2022)
Investor day · 50 slides · Jan 31, 2022